Macimorelin
A Phase III clinical trial showed that oral macimorelin was effective for the diagnosis of adult GHD with 82% sensitivity and 92% sensitivity at an ideal cutoff point of 2.7 GH / mL, comparable to the GHRH and arginine test [29]. Another phase Clinical trial III was completed in 2016, to compare its effectiveness with the insulin tolerance test (ClinicalTrial.gov Identi fi c: NCT02558829), and AEterna Zentaris announced the search for the approval of macimorelin for this indication by the FDA and by the European Medicines Agency in March 2017. A Phase II clinical study for the treatment of cancer cachexia is also underway (ClinicalTrial.gov Identi fi rer: NCT01614990).